ESR1 and breast cancer: Depletion of AFF4 by CRISPR-Cas9 reduced the recruitment of transcriptional elongation factors and RNA polymerase II to the ESR1 transcription start sites, decreased ESR1 gene expression, and inhibited the growth of ER-positive breast cancer cells.